CNCE Share Price Performance
US$0
0.00 (0.00%)
Sorry, there is currently no price data for this company.
Is Concert Pharmaceuticals (NASDAQ:CNCE) In A Good Position To Invest In Growth?
Jan 22
Concert Pharmaceuticals, Inc. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 0 Fair Values set on narratives written by author
CNCE Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
Concert Pharmaceuticals, Inc. Key Details
Last Reported Earnings
Sep 30, 2022
Next Reporting Earnings
n/a
- -2.04
- -220.53%
- -395.36%
- 0%
About CNCE
- Founded
- 2006
- Employees
- 64
- CEO
- WebsiteView website
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases. The company’s lead product candidate is CTP-543, which is in Phase III clinical trial for the treatment of alopecia areata, a serious autoimmune dermatological condition. It has strategic collaborations with Avanir Pharmaceuticals, Inc.; Jazz Pharmaceuticals, Inc.; Cipla Technologies; and Processa Pharmaceuticals. The company was incorporated in 2006 and is headquartered in Lexington, Massachusetts.
